Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Crocs' Mixed Investor Sentiment Hinges on North America Sales Trends, UBS Says

Crocs' Mixed Investor Sentiment Hinges on North America Sales Trends, UBS Says

MT newswireMT newswire2026/10/20 16:13
12:13 PM EDT, 10/20/2026 (MT Newswires) -- Crocs (CROX) is heading into Q3 results with mixed investor sentiment, as the market weighs solid international momentum against concerns over softer North America results, UBS Securities said Monday in a report. Investors remain focused on growth in Crocs' North America direct-to-consumer business, though the market is underestimating the drag from the company's recent shift in how it records Amazon.com (AMZN) revenue, UBS said. Crocs moved its Amazon business to a first-party model at the start of Q3 from a third-party model, meaning sales from the platform will now be recorded as wholesale rather than direct-to-consumer, the report said. Because wholesale generates less revenue per unit, UBS expects the change weigh on reported North America revenue for the full year. Conversations with investors point to a more bearish tone since Crocs' Q2 results, though the stock still does not fully reflect the likelihood of a below-consensus North America direct-to-consumer result, the report said. UBS outlined several benchmarks it expects Crocs to meet, including a mid-single-digit decline in North America direct-to-consumer revenue in Q3, a $0.15 EPS beat, unchanged full-year revenue guidance, a $0.15 increase to full-year EPS guidance, and Q4 EPS guidance of $3 to $3.10. Q3 results are expected Oct. 29. UBS maintained its neutral rating on Crocs with a price target of $120. Price: 120.53, Change: +0.35, Percent Change: +0.29
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475

Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.

智通财经•2026/10/21 07:13

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million

Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.

智通财经•2026/10/21 07:06